Back
Blueprint Medicines 10K Form
Sell
24
BPMC
Blueprint Medicines
Last Price:
$92.48
Seasonality Move:
5.74%
7 Day Trial
ALL ACCESS PASS
$
7
Key Filings
2023-10-26 | 10Q | BPMC/Blueprint Medicines Quarterly |
2023-08-02 | 10Q | BPMC/Blueprint Medicines Quarterly |
2023-05-04 | 10Q | BPMC/Blueprint Medicines Quarterly |
2022-11-01 | 10Q | BPMC/Blueprint Medicines Quarterly |
2022-08-02 | 10Q | BPMC/Blueprint Medicines Quarterly |
2022-05-03 | 10Q | BPMC/Blueprint Medicines Quarterly |
Receive BPMC News And Ratings
See the #1 stock for the next 7 days that we like better than BPMC
BPMC Financial Statistics
Sales & Book Value
Annual Sales: | $508.8M |
---|---|
Cash Flow: | $-30.3M |
Price / Cash Flow: | 0 |
Annual Sales: | $4.69 |
Price / Book: | 20.1 |
Profitability
EPS (TTM): | -1.08000 |
---|---|
Net Income (TTM): | $-67.1M |
Gross Margin: | $488.7M |
Return on Equity: | -24.43% |
Return on Assets: | -5.92% |
Blueprint Medicines Earnings Forecast
Key Blueprint Medicines Financial Ratios
-
The Gross Profit Margin over the past 10 years for BPMC is 96.04%.
-
The Selling, General & Administrative Expenses for BPMC have been equal to 70.61% of Gross Profit Margin.
-
The Research & Development expenses have been 67.10% of Revenue.
-
The Net Earning history of BPMC is -13.19% of Total Revenues.
-
Per Share Earnings over the last 12 years have been positive in 6 years.
Blueprint Medicines Stock Price Chart
Industry, Sector and Symbol
Stock Exchange: | NASDAQ |
---|---|
Industry: | Biotechnology |
Sector: | Health Care |
Current Symbol: | BPMC |
CUSIP: | 09627Y |
Website: | blueprintmedicines.com |
Debt
Debt-to-Equity Ratio: | 1.3 |
---|---|
Current Ratio: | 2.85 |
Quick Ratio: | 2.66 |
Price-to-Earnings
Trailing P/E Ratio: | 0 |
---|---|
Forward P/E Ratio: | 66.54 |
BPMC Technical Analysis vs Fundamental Analysis
Sell
24
Blueprint Medicines (BPMC)
is a Sell
Is Blueprint Medicines a Buy or a Sell?
-
Blueprint Medicines stock is rated a SellThe current Blueprint Medicines [BPMC] share price is $93.94. The Score for BPMC is 24, which is 52% below its historic median score of 50, and infers higher risk than normal.